Status:
RECRUITING
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Lead Sponsor:
University of California, Irvine
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This is a pilot study collecting data on the diversity and composition of gut microbiomes in subjects with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) while receiving treatment for NSCLC.
Eligibility Criteria
Inclusion
- 1\. Advanced/Metastatic non-small cell lung cancer NSCLC patients.
- 2\. The patient himself/herself must be 18 years of age on day of signing informed consent.
- 3\. The subject has signed the informed consent form.
- 4\. The patient must be eligible to receive FDA approved and non-approved PD1 inhibitors (i.e. pembrolizumab, nivolumab) or PDL1 inhibitor (i.e. atezolizumab, durvalumab) either single agent or as combination therapy with chemotherapy, or be eligible to receive FDA approved and non-approved tyrosine kinase inhibitors.
- 5\. The subject will be registered upon submission of the samples. When submitted on separate dates, the submission occurring later will be considered the date of registration
Exclusion
- 1\. Those subjects who are determined clinically unstable of the participation of this study as determined by the PI or treating physician will be excluded and asked to focus on their treatment.
Key Trial Info
Start Date :
January 31 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT06221800
Start Date
January 31 2024
End Date
December 1 2025
Last Update
February 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chao Family Comprehensive Cancer Center University of California, Irvine
Orange, California, United States, 92868